Bard gets exclusive endoluminal graft rights:
This article was originally published in Clinica
CR Bard has signed an exclusive agreement to distribute the CE-marked Endoluminal graft from Endologix in Europe and Australia. Endologix has initiated Japanese clinical studies and plans to start a US FDA Phase I IDE study in September. Bard, which has an option to buy the entire Irvine, California-based company before the end of 2000, says that the graft has demonstrated low endoleak rates and ease of delivery.
You may also be interested in...
Pain relief product sales grew 27% and upper respiratory sales 35% for the week ended 7 March as consumers respond to COVID-19, according to Nielsen data noted in a Jefferies report on consumer health purchasing trends. Private label market share is up slightly, while OTC purchases continue primarily in conventional stores.
Managing partner Corey Goodman said venBio didn’t have trouble closing its fund, because the venture capital firm prepared its investors for an economic downturn months ago.
The US FDA has proposed moving two categories of hepatitis C diagnostics to class II from class III because they pose relatively low risk.